病变细胞 z-bo 2020-10-23 348

　　In the United States, more than 20 million people suffer from neuropathic pain, and at least 25% of these cases are classified as unexplainable and are considered the basis of underlying sensory polyneuropathy (CSPN). Although there is no information to guide doctors in choosing CSPN drugs, researchers at Mizuri University School of Medicine and MU HealthCare conducted the first prospective comparative efficacy study. This study compared four drugs with different mechanisms of action in a large number of CSPN patients to determine the best drug for this situation. The study included 40 sites and recruited 402 patients over the age of 30 who were diagnosed with CSPN with a pain score of 4 or higher and a score of 10.

　　The participants were treated with one of four CSPN drugs: calcitonin (a tricyclic antidepressant), duloxetine (a serotonin norepinephrine reuptake inhibitor), and prevalin (a Kind of anti-epileptic drugs). ); or mexiretin (anti-arrhythmic drugs). The patient received the prescribed treatment for 12 weeks and was evaluated at 4, 8 and 12 weeks. Participants who reported at least 50% pain relief were considered reliable results. Patients who discontinued treatment due to side effects were also measured. Dr. Richard Barron, Senior Researcher and Deputy Prime Minister of the University of Missouri Department of Health, said: "This study not only focuses on whether the drug can reduce pain, but also the range of side effects. These four drugs provide doctors with effective treatment support. Evidence of neuropathy. It is used to provide and support the need for newer and more effective medications for neuropathic pain."

　　The highest incidence of calcitonin in the study (25%). , The second lowest exit rate (38%) and the highest total utility level. Duloxetine has the second highest treatment efficiency (23%) and the lowest dropout rate (37%). Pregavalin has the lowest efficacy (15%), while methicillin has the highest smoking cessation rate (58%). \r\n Baron said: "There is no clear good drug in this study. However, considering the efficacy and discontinuation of the drug, calcitonin and duloxetine are more effective in these four drugs. Other drugs are tested before, It is recommended to use Norbornin or Turin."

　　Other non-drugs that can be used to treat peripheral neuralgia, such as gabapentin, benasacine and other sodium channel inhibitors. .. Baron said that doctors can conduct more comparative efficacy studies on these drugs and build more databases to treat CSPN. His goal is to establish efficacy data for about 10 different drugs in CSPN. Recently, laboratory studies developed by a research team led by Johns Hopkins University bioengineers accurately detected, captured and analyzed the most deadly cells in the most common invasive brain cancer in adults. can do. This method can capture the highly aggressive and active cells of glioblastoma and help find new drugs to prevent or delay the spread of cancer. The test can also accurately predict which patients have the most active or least active glioblastoma.

　　"Because we have the unique ability to identify these deadly cells, we use this platform to screen for potential therapeutic agents and to invade and/or proliferate these cells. The author of this article, Konstantinos Konstantopoulos, "extends the survival time of patients", pointing out its purpose It is effective in preventing and ultimately using complex drugs. "Through proteomic analysis of these lethal cells, we have identified and characterized new targets that can prevent these highly invasive and proliferating cells. "

　　According to the paper, the test technique shows that every patient has a glioblastoma. Unable to predict results effectively. The paper pointed out that current single-cell analysis methods are too time-consuming and costly to "provide information to patients with glioblastoma because of their short survival time." The median survival time for the least aggressive type of cancer is about 6 months, and the median survival time for the most aggressive type of cancer is about 29 months. The Johns Hopkins University research team worked with researchers from the Mayyork Clinic and Stanford University to study glioblastoma, and last year they tested metastatic and non-metastatic breast cancer. The ability of cells to distinguish which cell has been shown to bind. This suggests that it may be applicable to other solid cancers. This method requires more tests on larger patient samples, but in a blinded retrospective study of 28 patients, the accuracy of predicting survival was 86% to 5 patients.